Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD09 in HPV16-positive cervical HSIL
NCT07047989Phase 1Recruiting
- Sponsor
- Newish Biotechnology
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NWRD09 in Squamous Intraepithelial Lesion (SIL), sponsored by Newish Biotechnology. Primary endpoints: Safety and Dose-limiting toxicity. Started Jun 2025; status: recruiting.
02
Drugs
NWRD09
03
Conditions
Squamous Intraepithelial Lesion (SIL)
Beyond the preview
Go deeper on NCT07047989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047989.